Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
What are your biggest takeaways from the MASH-TAG 2025 conference?
Related Questions
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
Do you recommend restarting GLP-1RA after bariatric surgery if they tolerated it before the surgery?
In what kind of patient scenario would you consider testing for inherited disorders of lipid metabolism in the evaluation of a patient with MASLD? What are you looking for clinically and in their workup and how do you proceed?
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
How would you approach GLP-1/GIP agonist use for MASLD management in a patient who had a prior episode of pancreatitis?
Is the Enhanced Liver Fibrosis (ELF) test superior to the FIB-4 test in the diagnosis of MASLD?
In what scenario would you opt to perform an MRI-PDFF in a patient with MASLD/MASH or in whom you suspect has this? Why would you opt for this over a Fibroscan or other NILDA?
What is your approach to the use of lipoprotein(a) as part of the cardiometabolic profile of a patient suspected to have or with MASLD/MASH?
How do you incorporate other pharmacologic bariatric/appetite suppressants in the context of their clinical care plan for MASLD?
In patients with Met-ALD, how do you approach their treatment plan?
